| # | Drug | Count |
|---|---|---|
| 0 | PEMBROLIZUMAB | 477 |
| 1 | NIVOLUMAB | 257 |
| 2 | CARBOPLATIN | 219 |
| 3 | PACLITAXEL | 179 |
| 4 | PACLITAXEL (AIBUMIN-BOUND) | 173 |
| 5 | IPILIMUMAB | 167 |
| 6 | LENVATINIB | 96 |
| 7 | CYCLOPHOSPHAMIDE | 88 |
| 8 | CYCLOPHOSPHAMIDE FOR INJECTION | 88 |
| 9 | CYCLOPHOSPHAMIDE INJECTION, SOLUTION | 88 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | TREMELIMUMAB | 20 | 0.0045 |
| 1 | PEMBROLIZUMAB | 477 | 0.0044 |
| 2 | EPIRUBICIN HYDROCHLORIDE | 26 | 0.0040 |
| 3 | IPILIMUMAB | 167 | 0.0038 |
| 4 | DOSTARLIMAB | 9 | 0.0036 |
| 5 | LENVATINIB | 96 | 0.0029 |
| 6 | NIVOLUMAB | 257 | 0.0026 |
| 7 | ENFORTUMAB VEDOTIN | 18 | 0.0023 |
| 8 | AZILSARTAN KAMEDOXOMIL | 6 | 0.0020 |
| 9 | SENNOSIDES A AND B | 3 | 0.0018 |
| # | Drug class | Count |
|---|---|---|
| 0 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 752 |
| 1 | Platinum-based Drug [EPC] | 267 |
| 2 | CTLA-4-directed Blocking Antibody [EPC] | 187 |
| 3 | Microtubule Inhibitor [EPC] | 180 |
| 4 | Kinase Inhibitor [EPC] | 99 |
| 5 | Alkylating Drug [EPC] | 88 |
| 6 | Folate Analog Metabolic Inhibitor [EPC] | 31 |
| 7 | Programmed Death Ligand-1 Blocker [EPC] | 31 |
| 8 | Corticosteroid [EPC] | 28 |
| 9 | Dihydropyridine Calcium Channel Blocker [EPC] | 21 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 752 | 0.0076 |
| 1 | CTLA-4-directed Blocking Antibody [EPC] | 187 | 0.0039 |
| 2 | Programmed Death Ligand-1 Blocker [EPC] | 31 | 0.0014 |
| 3 | Microtubule Inhibitor [EPC] | 180 | 0.0011 |
| 4 | Platinum-based Drug [EPC] | 267 | 0.0010 |
| 5 | Alkylating Drug [EPC] | 88 | 0.0004 |
| 6 | Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC] | 2 | 0.0003 |
| 7 | Dipeptidyl Peptidase 4 Inhibitor [EPC] | 8 | 0.0002 |
| 8 | Orexin Receptor Antagonist [EPC] | 4 | 0.0002 |
| 9 | Kinase Inhibitor [EPC] | 99 | 0.0002 |